Tiziana Advances Phase 2 Site Selection for Its Lead Clinical Program in Non-Active Secondary Progressive Multiple Sclerosis (SPMS) and The Company Prepares for Six-Month Clinical Data Update
–News Direct– By Rachael Green, Benzinga Tiziana Life Sciences Ltd. (NASDAQ: TLSA) recently announced the Company has initiated site selection for its lead intranasal anti-CD3 monoclonal antibody drug candidate foralumab…